[Progress in lentiviral vector-mediated gene therapy for Alzheimer's disease and Parkinson's disease].
[Progress in lentiviral vector-mediated gene therapy for Alzheimer's disease and Parkinson's disease].
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Beijing, CN · Author affiliation
CAS Center for Excellence in Biotic Interactions, College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are common neurodegenerative diseases in human. The pathogenesis of AD and PD is complex, and the current drugs and surgical treatments have not successfully alleviated or terminated the progression of the diseases. The lentiviral vector (LV) is a retroviral vector. In recent years, LV mediated gene therapy has been a hotspot to study the mechanisms of human disease and clinical drug discovery. This review summarizes the recent progresses in the treatment of AD and PD by the application of LV, and offers a prospect for its application.